Home > Insider Trading > Filing (0000950103-10-003769)

Filing Details

Accession Number:: 0000950103-10-003769
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-12-17 13:23:54
Reporting Period:: 2010-12-15

Filing Date:: 2010-12-17
Accepted Time:: 2010-12-17 13:23:54
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1369868	China Biologic Products Inc.	CBPO	Biological Products, (No Disgnostic Substances) (2836)	752308816

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
929408	Warburg Pincus & Co	450 Lexington Avenue New York NY 10017	No	No	Yes	No
1162870	Warburg Pincus Llc	450 Lexington Avenue New York NY 10017	No	No	Yes	No
1220638	Joseph Landy	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1239318	R Charles Kaye	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1322709	Warburg Pincus Partners Llc	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1414561	Warburg Pincus X, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1414564	Warburg Pincus X Llc	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1414565	Warburg Pincus Private Equity X, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No
1451560	Warburg Pincus X Partners, L.p.	C/O Warburg Pincus Llc 450 Lexington Avenue New York NY 10017	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-12-15	41,000	$15.83	4,711,000	No	4	P	Direct
Common Stock	Acquisiton	2010-12-15	9,000	$16.54	4,720,000	No	4	P	Direct
Common Stock	Acquisiton	2010-12-16	91,735	$16.64	4,811,735	No	4	P	Direct
Common Stock	Acquisiton	2010-12-16	8,265	$17.35	4,820,000	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.33 to $16.19, inclusive. The Warburg Pincus Reporting Persons (as defined below) undertake to provide to any security holder of China Biologic Products, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) through (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.49 to $16.84, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.12 to $17.10, inclusive.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.28 to $17.50, inclusive.
Warburg Pincus Private Equity X, L.P., a Delaware limited partnership ("WP X") is the holder of an aggregate of 4,670,580 shares of Common Stock. Warburg Pincus X Partners, L.P., a Delaware limited partnership ("WPP X" and together with WP X, the "Funds") is the holder of an aggregate of 149,420 shares of Common Stock. By reason of the provisions of Rule 16a-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Warburg Pincus X, L.P., a Delaware limited partnership and the sole general partner of each of the Funds ("WP X LP"), Warburg Pincus X LLC, a Delaware limited liability company ("WP X LLC") and the sole general partner of WP X LP, Warburg Pincus Partners, LLC, a New York limited liability company ("WPP LLC") and the sole member of WP X LLC, Warburg Pincus LLC, a New York limited liability company ("WP LLC") that manages each of the Funds, Warburg Pincus & Co., a New York general partnership ("WP") and the managing member of WPP LLC, (cont'd on Footnote 6)
and Messrs. Charles R. Kaye and Joseph P. Landy is a "Reporting Person" and collectively, the "Warburg Pincus Reporting Persons."
Information with respect to each of the Warburg Pincus Reporting Persons is given solely by such Warburg Pincus Reporting Persons, and no Warburg Pincus Reporting Person has responsibility for the accuracy or completeness of information supplied by another Warburg Pincus Reporting Person.
Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934, as amended, each of the Warburg Pincus Reporting Persons, other than the WP X and WPP X, herein states that this Statement shall not be deemed an admission that he or it is the beneficial owner of any of the shares of Common Stock covered by this Statement. Each of WP X LP, WP X LLC, WP Partners, WP, WP LLC, and Messrs. Kaye and Landy disclaims beneficial ownership of the Common Stock, except to the extent of its or his pecuniary interest in such shares of Common Stock.